First-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.

Phase 2 ILUSTRO cohort 4 evaluated adding zolbetuximab (anti‑CLDN18.2) and nivolumab to mFOLFOX6 as first‑line thera...

Continue ReadingFirst-line zolbetuximab plus mFOLFOX6 and nivolumab in unresectable CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: a phase 2 trial.

European Standard Clinical Practice Guideline and EXPeRT Recommendations for the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Neoplasms in Children and Adolescents.

This publication presents a European Standard Clinical Practice Guideline for pediatric gastroenteropancreatic neuroendo...

Continue ReadingEuropean Standard Clinical Practice Guideline and EXPeRT Recommendations for the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Neoplasms in Children and Adolescents.